Aardvark Therapeutics (AARD) vs PDS Biotechnology (PDSB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PDS Biotechnology (PDSB) has outperformed Aardvark Therapeutics (AARD) over the past year, gaining 2.0% versus a loss of 72.5%. Aardvark Therapeutics is the larger company by market cap ($102.5 million vs $99.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AARD | PDSB |
|---|---|---|
| Share price | $4.69 | $1.38 |
| Market cap | $102.53M | $99.65M |
| 1-day change | -0.53% | +34.95% |
| YTD return | -64.11% | +32.47% |
| 1-year return | -72.50% | +2.00% |
| 5-year return | — | -91.73% |
| EPS (TTM) | $-3.21 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.06 | $1.55 |
| 52-week low | $3.35 | $0.195 |
| Distance from 52-week high | -72.53% | -11.29% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +137.14% | +263.64% |
| Average volume | 208.11K | 23.24M |
| Shares outstanding | 21.88M | 72.47M |
| Employees | 28 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PDSB has outperformed AARD by 74.5 percentage points over the past year.
About Aardvark Therapeutics
AARD stock →Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
AARD vs PDSB FAQ
Which is bigger, Aardvark Therapeutics or PDS Biotechnology?
Aardvark Therapeutics (AARD) is larger, with a market capitalization of $102.53M compared with $99.65M for PDS Biotechnology (PDSB).
Which stock has performed better over the past year, AARD or PDSB?
PDSB returned +2.00% over the past 12 months, compared with -72.50% for AARD (price return, excluding dividends). Past performance does not predict future results.
Are Aardvark Therapeutics and PDS Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.